Wall Street brokerages predict that Fennec Pharmaceuticals Inc (NASDAQ:FENC) will report earnings per share (EPS) of ($0.24) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Fennec Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.21). Fennec Pharmaceuticals reported earnings per share of ($0.14) during the same quarter last year, which indicates a negative year over year growth rate of 71.4%. The business is expected to issue its next earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Fennec Pharmaceuticals will report full year earnings of ($0.85) per share for the current financial year, with EPS estimates ranging from ($0.92) to ($0.77). For the next financial year, analysts expect that the company will report earnings of $1.21 per share, with EPS estimates ranging from ($0.52) to $2.94. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Fennec Pharmaceuticals.

Fennec Pharmaceuticals (NASDAQ:FENC) last posted its earnings results on Friday, August 9th. The company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.10).

Several analysts have recently weighed in on FENC shares. Zacks Investment Research lowered shares of Fennec Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 15th. HC Wainwright set a $17.00 target price on Fennec Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 28th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $12.50.

Several institutional investors have recently added to or reduced their stakes in FENC. Geode Capital Management LLC increased its position in Fennec Pharmaceuticals by 16.0% in the 4th quarter. Geode Capital Management LLC now owns 39,489 shares of the company’s stock valued at $251,000 after acquiring an additional 5,441 shares in the last quarter. Hartford Financial Management Inc. increased its stake in shares of Fennec Pharmaceuticals by 65.0% in the 2nd quarter. Hartford Financial Management Inc. now owns 20,300 shares of the company’s stock valued at $81,000 after buying an additional 8,000 shares during the period. Atria Investments LLC acquired a new stake in shares of Fennec Pharmaceuticals in the 2nd quarter valued at $215,000. Paloma Partners Management Co bought a new stake in shares of Fennec Pharmaceuticals during the second quarter worth $218,000. Finally, United Services Automobile Association raised its position in shares of Fennec Pharmaceuticals by 32.1% during the second quarter. United Services Automobile Association now owns 229,983 shares of the company’s stock worth $920,000 after acquiring an additional 55,933 shares during the last quarter. 45.28% of the stock is owned by institutional investors and hedge funds.

NASDAQ:FENC traded up $0.06 on Friday, reaching $4.77. The stock had a trading volume of 45,749 shares, compared to its average volume of 65,759. The company has a market capitalization of $94.53 million, a P/E ratio of -9.54 and a beta of -0.03. Fennec Pharmaceuticals has a 1-year low of $3.26 and a 1-year high of $8.74. The stock has a fifty day moving average price of $4.39 and a 200-day moving average price of $4.59.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

Read More: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Fennec Pharmaceuticals (FENC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Fennec Pharmaceuticals (NASDAQ:FENC)

Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.